Home Newsfeeds William Blair Upgrades FibroGen to Outperform

William Blair Upgrades FibroGen to Outperform

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

byBenzinga Newsdesk

January 31, 2023

1 minute read

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

News

Unicycive Showcases Data on Kidney Disease Therapies at European Renal Congress

By Benzinga Newsdesk

May 28, 7:09 AM

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress Globe Newswire – Results from Preclinical Model of Hyperphosphatemia

UNCY

Recap: Capital City Bank Group Q2 Earnings

By Benzinga Insights

July 26, 8:50 AM

Capital City Bank Group (NASDAQ:CCBG) reported its Q2 earnings results on Tuesday, July 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

CCBG

Westamerica Banc Q2 EPS $0.94 Up From $0.84 YoY

By Benzinga Newsdesk

July 21, 10:48 AM

Westamerica Banc (NASDAQ:WABC) reported quarterly earnings of $0.94 per share. This is a 11.9 percent increase over earnings of $0.84 per share from the same period last year.

WABC

Kineta, Inc. Announces $6 Million Registered Direct Offering Of 1,425,179 Shares At A Price Of $4.21/Share Priced At-The-Market Under Nasdaq Rules

By Benzinga Newsdesk

April 20, 8:45 AM

Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it

William Blair Upgrades FibroGen to Outperform

Related Posts

Unicycive Showcases Data on Kidney Disease Therapies at European Renal Congress

Recap: Capital City Bank Group Q2 Earnings

Westamerica Banc Q2 EPS $0.94 Up From $0.84 YoY

Kineta, Inc. Announces $6 Million Registered Direct Offering Of 1,425,179 Shares At A Price Of $4.21/Share Priced At-The-Market Under Nasdaq Rules